Asciminib
Sign in to save this workspacePrimary targets: BCR_ABL, ABL1, ABL2_ARG · FDA status: FDA Approved
Selectivity scorecard
KISS
100.00
Gini
0.602
CATDS
0.022
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Asciminib. Strongest target: ABL2_ARG at 30.7% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | ABL2_ARG | 30.7% | 69.3% |
| 2 | NEK11 | 19.7% | 80.3% |
| 3 | PDK2_PDHK2 | 16.7% | 83.3% |
| 4 | ASK1_MAP3K5 | 16.4% | 83.6% |
| 5 | AURORA_A | 15.3% | 84.7% |
| 6 | MAPKAPK2 | 15.3% | 84.7% |
| 7 | WNK3 | 14.9% | 85.1% |
| 8 | ERK2_MAPK1 | 14.4% | 85.6% |
| 9 | EPHA6 | 13.8% | 86.2% |
| 10 | BMPR2 | 13.7% | 86.3% |
| 11 | RIPK2 | 13.6% | 86.4% |
| 12 | NEK4 | 13.5% | 86.5% |
| 13 | ARAF | 13.1% | 86.9% |
| 14 | PIM2 | 12.8% | 87.2% |
| 15 | TRKB | 12.8% | 87.2% |
| 16 | WNK1 | 12.4% | 87.6% |
| 17 | MARK3 | 12.4% | 87.6% |
| 18 | CDK17_CYCLIN_Y(PCTK2) | 12.3% | 87.7% |
| 19 | ERN2_IRE2 | 12.2% | 87.8% |
| 20 | SGK3_SGKL | 12.2% | 87.8% |
Selectivity landscape
Where Asciminib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Asciminib.
Atlas insights for Asciminib
Pathway-space view of what this drug actually does, drawn from the Pathway Atlas.
On-target vs off-target shadow
On-target0%
Off-target100%
Ghost (2nd-order)0%
| Pathway | Composition | Total |Π| |
|---|---|---|
| ADIPOGENESIS | 349.79 | |
| ALLOGRAFT_REJECTION | 798.30 | |
| ANDROGEN_RESPONSE | 323.46 | |
| ANGIOGENESIS | 85.36 | |
| APICAL_JUNCTION | 822.96 | |
| APICAL_SURFACE | 130.13 | |
| APOPTOSIS | 1134.25 | |
| BILE_ACID_METABOLISM | 114.77 | |
| CHOLESTEROL_HOMEOSTASIS | 149.05 | |
| COAGULATION | 88.79 | |
| COMPLEMENT | 495.43 | |
| DNA_REPAIR | 273.00 | |
| E2F_TARGETS | 1065.90 | |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 314.23 | |
| ESTROGEN_RESPONSE_EARLY | 576.97 | |
| ESTROGEN_RESPONSE_LATE | 500.97 | |
| FATTY_ACID_METABOLISM | 82.75 | |
| G2M_CHECKPOINT | 952.45 | |
| GLYCOLYSIS | 389.05 | |
| HEDGEHOG_SIGNALING | 58.50 | |
| HEME_METABOLISM | 310.60 | |
| HYPOXIA | 747.73 | |
| IL2_STAT5_SIGNALING | 435.97 | |
| IL6_JAK_STAT3_SIGNALING | 540.22 | |
| INFLAMMATORY_RESPONSE | 570.03 | |
| INTERFERON_ALPHA_RESPONSE | 100.64 | |
| INTERFERON_GAMMA_RESPONSE | 740.82 | |
| KRAS_SIGNALING_DN | 173.23 | |
| KRAS_SIGNALING_UP | 301.17 | |
| MITOTIC_SPINDLE | 762.32 | |
| MTORC1_SIGNALING | 535.27 | |
| MYC_TARGETS_V1 | 620.16 | |
| MYC_TARGETS_V2 | 183.20 | |
| MYOGENESIS | 545.66 | |
| NOTCH_SIGNALING | 63.43 | |
| OXIDATIVE_PHOSPHORYLATION | 110.59 | |
| P53_PATHWAY | 682.49 | |
| PANCREAS_BETA_CELLS | 90.62 | |
| PEROXISOME | 172.18 | |
| PI3K_AKT_MTOR_SIGNALING | 1137.99 | |
| PROTEIN_SECRETION | 265.09 | |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 88.70 | |
| SPERMATOGENESIS | 297.20 | |
| TGF_BETA_SIGNALING | 351.10 | |
| TNFA_SIGNALING_VIA_NFKB | 745.48 | |
| UNFOLDED_PROTEIN_RESPONSE | 274.32 | |
| UV_RESPONSE_DN | 665.22 | |
| UV_RESPONSE_UP | 530.39 | |
| WNT_BETA_CATENIN_SIGNALING | 362.72 | |
| XENOBIOTIC_METABOLISM | 257.23 |
Hallmarks-of-Cancer reach
Anti-tumor matches — the "ideal patient" search
| Sample | Cancer type | cos to ideal |
|---|---|---|
| EPT0291 | EPN | 0.873 |
| TCGA-CF-A5U8-01A-11R-A28M-07 | — | 0.849 |
| SRR12202498 | — | 0.838 |
| SRR1443713 | GTEX | 0.836 |
| R247 | — | 0.830 |
Annotations
Sign in to read and post annotations.
Loading…